These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

185 related articles for article (PubMed ID: 31843065)

  • 1. PSMA-Based Theranostics: A Step-by-Step Practical Approach to Diagnosis and Therapy for mCRPC Patients.
    Ahmadzadehfar H; Rahbar K; Essler M; Biersack HJ
    Semin Nucl Med; 2020 Jan; 50(1):98-109. PubMed ID: 31843065
    [TBL] [Abstract][Full Text] [Related]  

  • 2. New Strategies in Prostate Cancer: Prostate-Specific Membrane Antigen (PSMA) Ligands for Diagnosis and Therapy.
    Haberkorn U; Eder M; Kopka K; Babich JW; Eisenhut M
    Clin Cancer Res; 2016 Jan; 22(1):9-15. PubMed ID: 26728408
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The
    Scarpa L; Buxbaum S; Kendler D; Fink K; Bektic J; Gruber L; Decristoforo C; Uprimny C; Lukas P; Horninger W; Virgolini I
    Eur J Nucl Med Mol Imaging; 2017 May; 44(5):788-800. PubMed ID: 28083690
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Third-line treatment and
    von Eyben FE; Roviello G; Kiljunen T; Uprimny C; Virgolini I; Kairemo K; Joensuu T
    Eur J Nucl Med Mol Imaging; 2018 Mar; 45(3):496-508. PubMed ID: 29247284
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Radioligand therapy of metastatic castration-resistant prostate cancer: current approaches.
    Awang ZH; Essler M; Ahmadzadehfar H
    Radiat Oncol; 2018 May; 13(1):98. PubMed ID: 29792198
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Predictive Factors of Response and Overall Survival in Patients with Castration-Resistant Metastatic Prostate Cancer Undergoing
    Ahmadzadehfar H; Essler M
    J Nucl Med; 2018 Jul; 59(7):1033-1034. PubMed ID: 29653975
    [No Abstract]   [Full Text] [Related]  

  • 7. Why Targeting of PSMA Is a Valuable Addition to the Management of Castration-Resistant Prostate Cancer: The Urologist's Point of View.
    Hadaschik BA; Boegemann M
    J Nucl Med; 2017 Aug; 58(8):1207-1209. PubMed ID: 28522737
    [No Abstract]   [Full Text] [Related]  

  • 8. Efficacy Against Human Prostate Cancer by Prostate-specific Membrane Antigen-specific, Transforming Growth Factor-β Insensitive Genetically Targeted CD8
    Zhang Q; Helfand BT; Carneiro BA; Qin W; Yang XJ; Lee C; Zhang W; Giles FJ; Cristofanilli M; Kuzel TM
    Eur Urol; 2018 May; 73(5):648-652. PubMed ID: 29275833
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Recovery of Renal Function Under PSMA Mediated Radioligand Therapy of Advanced Metastasized Castration Resistant Prostate Cancer.
    Ries M; Khreish F; Berchem G; Ezziddin S
    Clin Nucl Med; 2019 Sep; 44(9):730-731. PubMed ID: 31283606
    [TBL] [Abstract][Full Text] [Related]  

  • 10. 177Lu-PSMA and 177Lu-DOTATATE Therapy in a Patient With Metastatic Castration-Resistant Prostate Cancer and Neuroendocrine Differentiation.
    Assadi M; Pirayesh E; Rekabpour SJ; Zohrabi F; Jafari E; Nabipour I; Esmaili A; Amini A; Ahmadzadehfar H
    Clin Nucl Med; 2019 Dec; 44(12):978-980. PubMed ID: 31689280
    [TBL] [Abstract][Full Text] [Related]  

  • 11. PSMA-Based Radioligand Therapy for Metastatic Castration-Resistant Prostate Cancer: The Bad Berka Experience Since 2013.
    Kulkarni HR; Singh A; Schuchardt C; Niepsch K; Sayeg M; Leshch Y; Wester HJ; Baum RP
    J Nucl Med; 2016 Oct; 57(Suppl 3):97S-104S. PubMed ID: 27694180
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Dosimetry for (177)Lu-DKFZ-PSMA-617: a new radiopharmaceutical for the treatment of metastatic prostate cancer.
    Delker A; Fendler WP; Kratochwil C; Brunegraf A; Gosewisch A; Gildehaus FJ; Tritschler S; Stief CG; Kopka K; Haberkorn U; Bartenstein P; Böning G
    Eur J Nucl Med Mol Imaging; 2016 Jan; 43(1):42-51. PubMed ID: 26318602
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The potential of PSMA-targeted alpha therapy in the management of prostate cancer.
    Filippi L; Chiaravalloti A; Schillaci O; Bagni O
    Expert Rev Anticancer Ther; 2020 Oct; 20(10):823-829. PubMed ID: 32820953
    [TBL] [Abstract][Full Text] [Related]  

  • 14. 225Ac-PSMA-617 for PSMA-Targeted α-Radiation Therapy of Metastatic Castration-Resistant Prostate Cancer.
    Kratochwil C; Bruchertseifer F; Giesel FL; Weis M; Verburg FA; Mottaghy F; Kopka K; Apostolidis C; Haberkorn U; Morgenstern A
    J Nucl Med; 2016 Dec; 57(12):1941-1944. PubMed ID: 27390158
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Visceral Metastases as Predictors of Response and Survival Outcomes in Patients of Castration-Resistant Prostate Cancer Treated With 177Lu-Labeled Prostate-Specific Membrane Antigen Radioligand Therapy: A Systematic Review and Meta-analysis.
    Satapathy S; Mittal BR; Sood A
    Clin Nucl Med; 2020 Dec; 45(12):935-942. PubMed ID: 32956129
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prostate-Specific Membrane Antigen Ligand Positron Emission Tomography in Men with Nonmetastatic Castration-Resistant Prostate Cancer.
    Fendler WP; Weber M; Iravani A; Hofman MS; Calais J; Czernin J; Ilhan H; Saad F; Small EJ; Smith MR; Perez PM; Hope TA; Rauscher I; Londhe A; Lopez-Gitlitz A; Cheng S; Maurer T; Herrmann K; Eiber M; Hadaschik B
    Clin Cancer Res; 2019 Dec; 25(24):7448-7454. PubMed ID: 31511295
    [TBL] [Abstract][Full Text] [Related]  

  • 17. PSMA-Targeted Radionuclide Therapy of Metastatic Castration-Resistant Prostate Cancer with 177Lu-Labeled PSMA-617.
    Kratochwil C; Giesel FL; Stefanova M; Benešová M; Bronzel M; Afshar-Oromieh A; Mier W; Eder M; Kopka K; Haberkorn U
    J Nucl Med; 2016 Aug; 57(8):1170-6. PubMed ID: 26985056
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prostate-specific Membrane Antigen Heterogeneity and DNA Repair Defects in Prostate Cancer.
    Paschalis A; Sheehan B; Riisnaes R; Rodrigues DN; Gurel B; Bertan C; Ferreira A; Lambros MBK; Seed G; Yuan W; Dolling D; Welti JC; Neeb A; Sumanasuriya S; Rescigno P; Bianchini D; Tunariu N; Carreira S; Sharp A; Oyen W; de Bono JS
    Eur Urol; 2019 Oct; 76(4):469-478. PubMed ID: 31345636
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Repeated PSMA-targeting radioligand therapy of metastatic prostate cancer with
    Afshar-Oromieh A; Haberkorn U; Zechmann C; Armor T; Mier W; Spohn F; Debus N; Holland-Letz T; Babich J; Kratochwil C
    Eur J Nucl Med Mol Imaging; 2017 Jun; 44(6):950-959. PubMed ID: 28280855
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Theranostics for Advanced Prostate Cancer: Current Indications and Future Developments.
    Farolfi A; Fendler W; Iravani A; Haberkorn U; Hicks R; Herrmann K; Walz J; Fanti S
    Eur Urol Oncol; 2019 Mar; 2(2):152-162. PubMed ID: 31017091
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.